Abstract:The majority of patients with non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations inevitably progress in stage despite an initial substantial and rapid response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Previous research indicates that hypoxia may be associated with resistance to EGFR-TKIs in EGFR mutation-positive NSCLC. Therefore, the present study regulated the activity of hypoxia-inducible factor-1 (HIF-1) signaling pathway to observe if it is able to alter the sensitivity of lung cancer cells to gefitinib. The present study selected 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) and dimethyloxalylglycine (DMOG) as a HIF-1 signaling pathway inhibitor and activator, respectively, on HCC827 cells. Cells were incubated with different treatments for different durations: A blank control, DMOG, gefitinib, or DMOG and gefitinib combined, for 36 and 48 h; and then a blank control, YC-1, gefitinib, or YC-1 and gefitinib combined, for 16 and 28 h. A western blot analysis assay was performed to evaluate the protein expression levels of HIF-1α and phosphorylated hepatocyte growth factor receptor (p-MET), an MTT assay was used to determine cell proliferation, a colony formation assay was used to investigate the colony-forming ability and a wound healing assay was used to test the cell migration ability. Additionally, Pearson's correlation analysis was used to evaluate the correlation between p-Met and HIF-1α expression levels. Finally, it was identified that gefitinib and DMOG combined notably improve the growth and cell migration ability of HCC827 cells, compared with gefitinib alone. When gefitinib and YC-1 were combined, the inhibiting effect on the growth and cell migration ability of HCC827 cells was substantially enhanced, compared with the control cells. Pearson's correlation analysis revealed that the p-Met expression level had a strong positive correlation with HIF-1α expression levels. Thus, it was concluded that the HIF-1 signaling pathway influences the sensitivity of HCC827 cells to gefitinib. The positive correlation between p-Met and HIF-1α expression levels may be the underlying mechanism of the HIF-1 signaling pathway influencing the sensitivity of HCC827 cells to gefitinib.

Direct Interaction Between Surface Β1,4-Galactosyltransferase 1 and Epidermal Growth Factor Receptor (EGFR) Inhibits EGFR Activation in Hepatocellular Carcinoma

O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling

Cell Surface Beta 1,4-Galactosyltransferase 1 Promotes Apoptosis by Inhibiting Epidermal Growth Factor Receptor Pathway

Constitutively Active PKB/Akt Inhibited Apoptosis and Down-Regulated Β1,4-Galactosyltransferase 1 in Hepatocarcinoma Cells

Inhibitory Effect of EGFR Antisense Oligodeoxynucleotide on Human Hepatoma Cell Line.

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

Two Specific Inhibitors of the Phosphatidylinositol 3-Kinase LY294002 and Wortmannin Up-Regulate Β1,4-Galactosyltransferase I and Thus Sensitize SMMC-7721 Human Hepatocarcinoma Cells to Cycloheximide-Induced Apoptosis

Effect of P58gta on Β-1,4-galactosyltransferase 1 Activity and Cell-Cycle in Human Hepatocarcinoma Cells

Study on the Effects of Overexpression of Exogenous Notch1 in Tongue Squamous Cell Carcinoma Cells on Cell Growth and Expression of Epidermal Growth Factor Receptor in Vitro

Silencing GTSE-1 Expression Inhibits Proliferation and Invasion of Hepatocellular Carcinoma Cells

MiR-875-5p suppresses Gli1 to alter the hedgehog signaling pathway, which in turn has hepatocellular cancer-related tumor suppressing properties

[Cross-Talk Between Notch1 and Epidermal Growth Factor Receptor Signalling in Regulating Cell Proliferation of Human Tongue Squamous Carcinoma Cells].

Involvement of β 1,4 galactosyltransferase 1 and Galβ 1→4GlcNAc groups in human hepatocarcinoma cell apoptosis

O‐GlcNAc transferase activates stem‐like cell potential in hepatocarcinoma through O‐GlcNAcylation of eukaryotic initiation factor 4E

Regulation of the Beta 1,4-Galactosyltransferase I Promoter by E2f1

Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells

Down-regulation of β1,4-galactosyltransferase gene expression by cell-cycle suppressor gene p16

EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma

The Effect of Receptor Protein Tyrosine Phosphatase Kappa on the Change of Cell Adhesion and Proliferation Induced by N-acetylglucosaminyltransferase V.

The phyto-chemical (-)-epigallocatechin gallate suppresses gene expression of epidermal growth factor receptor in rat hepatic stellate cells in vitro by reducing the activity of Egr-1

Targeting A Novel Cancer-Driving Protein (Laptm4b-35) by A Small Molecule (ets) to Inhibit Cancer Growth and Metastasis